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Abstract
 
Interleukin (IL)-1 is a proinflammatory cytokine that plays important roles in inflammation,
host defense, and the neuro-immuno-endocrine network. IL-1 receptor antagonist (ra) is an
endogenous inhibitor of IL-1 and is supposed to regulate IL-1 activity. However, its patho-
physiological roles in a body remain largely unknown. To elucidate the roles of IL-1ra, IL-1ra–
deficient mice were produced by gene targeting, and pathology was analyzed on different genetic
backgrounds. We found that all of the mice on a BALB/cA background, but not those on a
C57BL/6J background, spontaneously developed chronic inflammatory polyarthropathy. Histo-
pathology showed marked synovial and periarticular inflammation, with articular erosion
caused by invasion of granulation tissues closely resembling that of rheumatoid arthritis in hu-
mans. Moreover, elevated levels of antibodies against immunoglobulins, type II collagen, and
double-stranded DNA were detected in these mice, suggesting development of autoimmunity.
Proinflammatory cytokines such as IL-1
 
b
 
, IL-6, and tumor necrosis factor 
 
a 
 
were overexpressed
in the joints, indicating regulatory roles of IL-1ra in the cytokine network. We thus show
that IL-1ra gene deficiency causes autoimmunity and joint-specific inflammation and suggest
that IL-1ra is important in maintaining homeostasis of the immune system. Possible involvement
of IL-1ra gene deficiency in RA will be discussed.
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Introduction
 
Rheumatoid arthritis (RA)
 
1
 
 is a systemic, chronic, inflam-
matory disorder expressed most commonly in the joints. Ap-
proximately 1% of adults worldwide are estimated to be af-
fected with this disease and suffer from substantial pain and
disability (1). Although various factors, including genetic
factors, environmental factors, and infectious agents, have
been suggested as causes of the disease (2), so far the etio-
pathogenesis has not been elucidated completely. Patients
often produce autoantibodies against various self-substances
such as IgG (rheumatoid factor [RF]), type II collagen
(IIC), and nuclear antigens, suggesting an autoimmune na-
ture of the disease (1). Moreover, various proinflammatory
cytokines, including IL-1, IL-6, and TNF-
 
a
 
, are overex-
pressed in the joints of RA patients (2). As these cytokines
can induce inflammation, promote synovial cell growth,
and induce differentiation of osteoclasts, it is suspected that
they may play an important role in the development of the
disease (2). IL-1 seems especially crucial, because injection
of IL-1 into normal rabbit joints causes severe arthritis (3),
and injection of anti–IL-1 antibody or IL-1 receptor antag-
onist (ra) into affected joints ameliorates the disease (4–7).
IL-1 is a major mediator of inflammation and is produced
by various types of cells, including macrophages, monocytes,
and synovial lining cells (8). Three gene products, IL-1
 
a
 
,
IL-1
 
b
 
, and IL-1ra, are known as the members of the IL-1
family that bind to IL-1Rs. IL-1
 
a
 
 and IL-1
 
b
 
 exert similar bi-
ological activities through the IL-1 type I receptor (IL-1RI;
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reference 9), whereas IL-1ra is a naturally occurring inhibi-
tor of IL-1 and competes for the receptor (10, 11). IL-1
signaling is also regulated by the IL-1 type II receptor (IL-
1RII), a decoy receptor (12). Four isoforms of IL-1ra pro-
tein are synthesized by alternative splicing from a single gene;
one is a secreted form with a signal polypeptide, and the
other three exist intracellularly (13–16). All four isoforms
can inhibit IL-1 activities. IL-1ra production is induced by
a number of other cytokines, viral products, and acute phase
proteins and is augmented in patients with autoimmune
and inflammatory diseases, suggesting that this cytokine
may play regulatory roles in those diseases (17).
It has been shown that IL-1 can induce many other genes.
For example, we have shown that IL-1
 
b
 
 induces IL-1
 
a
 
,
and vice versa (18). IL-1 also induces IL-6 and cyclooxyge-
nase (COX)-2 (19). These factors, together with IL-1 or in
a cascade, exhibit pleiotropic effects on an animal, includ-
ing induction of inflammation and acute phase responses,
host defense against bacterial and viral infection, activation
of the immune system including thymocyte maturation and
Th2 cell proliferation, and enhancement of bone metabo-
lism by activating osteoclasts to secrete metalloproteases (19,
20). Recently, we showed that IL-1 is also involved in fever
development and activation of the hypothalamic-pituitary-
adrenal axis (18). However, the role of IL-1 as well as IL-1ra
in normal physiology and diseases has not been completely
elucidated. Thus, we have recently produced mice deficient
in genes for IL-1
 
a
 
, IL-1
 
b
 
, and IL-1ra using 129 mouse–
derived embryonic stem cells to assess roles of these cyto-
kines in a living animal (18). These mice showed no appar-
ent abnormalities, except that IL–1ra deficient (IL-1ra
 
2
 
/
 
2
 
)
mice showed some growth retardation.
We backcrossed these mice to several lines of inbred
mice of different genetic backgrounds to see the difference
of inflammatory reactions among strains. Interestingly, we
found that IL-1ra
 
2
 
/
 
2
 
 mice on a BALB/cA background spon-
taneously developed chronic inflammatory arthropathy that
closely resembled RA in humans. Overexpression of proin-
flammatory cytokine genes was observed in the joints of
these mice before onset of the disease. Elevation of serum
Ig levels and autoantibody production was observed in these
mice, suggesting development of autoimmunity. We will
discuss the importance of IL-1ra in the homeostasis of the
immune system and its possible involvement in human auto-
immune diseases.
 
Materials and Methods
 
Production of IL-1ra
 
2
 
/
 
2
 
 Mice.
 
IL-1ra
 
2
 
/
 
2
 
 mice were produced
by replacing the entire exons of the secreted form with the 
 
neo
 
gene by homologous recombination as described (18). In these
mutant mice, all four isoforms of the IL-1ra were destroyed.
These mice were backcrossed to either BALB/cA or C57BL/6J
strain mice for five to eight generations. Then, heterozygous mice
were intercrossed with each other to obtain homozygous mutant
mice. Mice were kept under specific pathogen–free conditions in
an environmentally controlled clean room at the Laboratory Ani-
mal Research Center, Institute of Medical Science, University of
Tokyo. The experiments were carried out according to the insti-
tutional ethical guidelines for animal experiments and safety
guidelines for gene manipulation experiments.
 
Clinical Evaluation.
 
Incidence of arthritis was judged macro-
scopically. Each joint was examined weekly for swelling and red-
ness. The severity of arthritis was graded on a scale of 0–3 for
each paw for degree of redness and swelling. Grade 0 
 
5 
 
normal,
grade 1 
 
5 
 
light swelling of the joint and/or redness of the foot-
pad, grade 2 
 
5 
 
obvious swelling of the joint, and grade 3 
 
5 
 
severe
swelling and fixation of the joint. A severity score was calculated
for the four limbs (maximum 12 points for individual mice).
 
Histological Examination.
 
Joints were fixed in 10% phosphate-
buffered formalin, decalcified in 10% EDTA-4Na, and embedded
in paraffin. Sections (4 
 
m
 
m) were stained with hematoxylin/eosin.
 
FACS
 
®
 
 Analysis.
 
Single-cell suspensions from thymi, spleens,
and LNs were prepared, and 10
 
6
 
 cells were pretreated with FcR-
blocking antibody and stained with the following mAbs for 45 min.
Cells were washed with FACS solution (HBSS/20% FCS) and ana-
lyzed with a FACScan™ cytometer using the LYSIS II™ program
(Becton Dickinson). mAbs used for the staining were anti-CD45R/
B220–PE (RA3-6B2), rat anti–CD3-
 
e
 
–FITC (145-2C11), anti-
CD8a–FITC (Ly-2), anti-CD4–PE, anti-CD44–PE, and anti-
CD25–PE (PharMingen).
 
Antibody Titration.
 
Serum levels of IgG, IgM, and IgE were
determined by ELISA as previously described (21). In brief, poly-
vinyl microtiter plates (Falcon MicroTest III; Becton Dickinson)
were coated with 50 
 
m
 
l of rabbit anti–mouse IgG (8.7 
 
m
 
g/ml;
DAKO Corp.), anti–mouse IgM (2 
 
m
 
g/ml; Zymed Labs., Inc.), or
anti–mouse IgE (2 
 
m
 
g/ml; PharMingen) in PBS. For autoanti-
body titration, plates were coated with 50 
 
m
 
l of heat-denatured
rabbit IgG (50 
 
m
 
g/ml) or bovine IIC (20 
 
m
 
g/ml) in TBS (25 mM
Tris/HCl and 140 mM NaCl, pH 7.4). For the DNA, 50 
 
m
 
l of
double-stranded (ds)DNA (1 
 
m
 
g/ml) in TBS was placed in wells
of microtiter plates that had been coated with poly-
 
l
 
-lysine and
dried overnight at 37
 
8
 
C. The plates were blocked with 1% skim
milk (Coop)/5 mM EDTA/0.02% NaN
 
3
 
/TBS (blocking buffer)
for 1 h at room temperature. Mouse serum was diluted by block-
ing buffer and added to each well. Alkaline phosphatase–conju-
gated goat anti–mouse IgG antibody (Zymed Labs., Inc.) or anti–
mouse IgM antibody (Zymed Labs., Inc.) in blocking buffer was
added as the secondary antibody. After washing with Tween 20/
TBS, 100 
 
m
 
l of 1 mg/ml 
 
p
 
-nitrophenylphosphate (Sigma Chemi-
cal Co.) in 50 mM NaHCO
 
3
 
/5 mM MgCl
 
2
 
, pH 9.5, was added,
and the absorbance at 415 nm was measured by ELISA micro-
reader (MTP-120; Colona). IgG and IgM concentrations were
determined using mouse standard serum NOR-02/93 (Nordic Im-
munology), purified mouse myeloma IgM (Zymed Labs., Inc.), and
purified mouse IgE (PharMingen), respectively, as the standards.
 
Northern Blot Hybridization Analysis.
 
Total RNA was isolated
from the joints by an acid guanidium thiocyanate-phenol-chloro-
form extraction method, and poly (A)
 
1
 
 RNA was purified using
the QuickPrep Micro mRNA Purification Kit (Pharmacia). North-
ern blot hybridization was performed as described (18). Probes for
IL-1ra, IL-1
 
a
 
, IL-1
 
b
 
, IL-6, TNF-
 
a
 
, COX-2, and 
 
b
 
-actin were de-
scribed previously (18). The intensity of the bands on the autoradio-
gram was estimated by the BAS 2000 system (Fuji Photo Film Co.).
Mouse IL-1RI and IL-1RII probes were prepared by RT-PCR
using RNA preparation from the mouse spleen. The PCR primers
were 5
 
9
 
-TCGCAAGTGTCCTCTTACTCC-3
 
9
 
 and 5
 
9
 
-GTGG-
TAAGTGTGTTGCTGCC-3
 
9
 
 for IL-1RI and 5
 
9
 
-TGGACTCT-
TCTCAGCTGATCC-3
 
9
 
 and 5
 
9
 
-TGATCAGAGACAGAGGT-
GCC-3
 
9 
 
for IL-1RII. PCR cycles were 94
 
8
 
C for 1 min, 59
 
8
 
C for
1 min, and 72
 
8
 
C for 2 min (40 cycles). 
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Results
 
Development of Arthropathy in IL-1ra
 
2
 
/
 
2
 
 Mice.
 
IL-1ra
 
2
 
/
 
2
 
mice were produced as described (18) and backcrossed to ei-
ther BALB/cA or C57BL/6J mice. We noticed that, although
(129 
 
3
 
 C57BL/6J) F1 hybrid mice looked normal, IL-1ra
 
2
 
/
 
2
 
mice after backcrossing five generations to BALB/cA mice
spontaneously developed chronic inflammatory arthropathy.
In those mice, swelling and redness were observed in mul-
tiple joints. These symptoms were most remarkable at the
ankle joint of the hindlimbs (Fig. 1, a and b) and appeared
less frequently in the finger joints. The joints of the fore-
limbs also developed arthropathy, although the incidence
and severity were low. Histological analysis of the ankle
joints showed marked synovial and periarticular inflamma-
tion, with articular erosion caused by invasion of granula-
tion tissues (Fig. 1, c and d). Proliferation of synovial lining
cells was remarkable, and invasion of inflammatory cells,
including lymphocytes and neutrophils, was seen forming
pannus (Fig. 1 d). Invasion of inflammatory cells mainly
consisting of neutrophils was observed in the synovial space.
Fibrin clots were also seen in this space (Fig. 1 e). Bone
erosion was also remarkable, and the bone matrix was re-
placed with fibroblastic cells with marked activation of os-
teoclasts (Fig. 1 f). These histological findings were similar
to those for RA in humans. Other histopathological abnor-
Figure 1. Histopathology of
the ankle joints of BALB/cA IL-
1ra2/2 mice. The ankles of a nor-
mal IL-1ra1/1 mouse (a) and an
affected IL-1ra2/2 mouse (b) at
16 wk of age. Swelling and red-
ness of the joints was observed in
the IL-1ra2/2 mouse. Micro-
scopic observation of the joints of
an IL-1ra1/1 mouse (c) and an
IL-1ra2/2 mouse (d), showing
erosive destruction of the bone in
the IL-1ra2/2 mouse (arrow-
heads). Infiltration of inflamma-
tory cells (arrows) and prolifera-
tion of the lining cells of the
synovial membrane (w) were re-
markable. (e) Neutrophil infiltra-
tion in the articular cavity (arrow-
heads) and deposition of fibrin
clots (w). (f) Pannus formation;
note the activation of osteoclasts
(arrowheads). Scale bars: c and d,
100 mm; e and f, 50 mm. 
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malities were not found in IL-1ra
 
2
 
/
 
2
 
 mice, except for smaller
body size (18).
The early sign of arthritis could be detected in IL-1ra
 
2
 
/
 
2
 
mice of the BALB/cA background as early as 5 wk of age.
The incidence gradually increased, and 
 
.
 
80% of mice be-
came arthritic before 8 wk of age (Fig. 2 a). By 13 wk of age,
all of the IL-1ra
 
2
 
/
 
2
 
 mice developed arthritis, whereas none
of the wild-type (IL-1ra
 
1
 
/
 
1
 
) or heterozygous (IL-1ra
 
1
 
/
 
2
 
) lit-
termates did (data not shown). Arthritic severity score was
also increased gradually in IL-1ra
 
2
 
/
 
2
 
 mice (Fig. 2 b). Inci-
dence and severity scores of arthritis were not significantly
different between males and females (Fig. 2, a and b). It was
thus shown that deficiency in the IL-1ra gene causes arthritis.
In contrast, none of the IL-1ra
 
2
 
/
 
2
 
 mice on a C57BL/6J
background developed the disease at all at 16 wk of age,
when all of the BALB/cA IL-1ra
 
2
 
/2 mice did (Table I). In
older mice, arthritis developed at a low incidence. These
observations indicate that a genetic factor(s) other than IL-
1ra is involved in the development of this arthritis.
Development of Autoimmunity in IL-1ra2/2 Mice. Histolog-
ical analyses revealed that lymphoid tissues such as spleens
and lymph nodes were enlarged in these mice; average
spleen weight was 1.5-fold and that of lymph nodes was
1.8-fold heavier than in wild-type littermates at 16 wk of
age (P , 0.001, t test), suggesting an activation of the im-
mune system in arthritic IL-1ra2/2 mice. However, the
proportion of CD441 or CD251 T cell population as well
as the T and B cell ratio and CD41 and CD81 T cell ratio
was not significantly altered in IL-1ra2/2 compared with
IL-1ra1/1 mice (data not shown). These observations indi-
cate that IL-1ra deficiency does not significantly affect T
cell and B cell composition in normal physiology.
We next investigated Ig levels in the serum. The IgM
concentration was not changed in these mice (Fig. 3 a). In
contrast, total IgG and IgE levels were elevated two- to
threefold at 16 wk of age (Fig. 3 a). Among the IgG sub-
classes, the level of IgG1, the major component of serum
IgG, was significantly elevated, whereas IgG2a and IgG2b
levels were not changed and the IgG3 level was slightly re-
duced compared with IL-1ra1/1 mice (Fig. 3 b).
As involvement of autoimmunity was suggested in the de-
velopment of RA, we next measured autoantibody levels rel-
evant to RA in the sera of these mice. As shown in Fig. 3 c,
antibody levels against IgG (IgG class RF), IIC, and dsDNA
were significantly elevated in IL-1ra2/2 BALB/cA mice at
16 wk of age compared with IL-1ra1/1 and IL-1ra1/2 litter-
mates, whereas IgM class RF was not significantly elevated in
these mice. On the other hand, autoantibody levels were not
significantly elevated in IL-1ra2/2 mice on the C57BL/6J
background in which no arthritis developed (Fig. 3 d). Au-
toantibody levels, however, did not necessarily correlate to
the severity score of arthritis, and even BALB/cA IL-1ra2/2
mice with low antibody levels developed arthritis at 16 wk of
age. These observations suggest that IL-1ra deficiency causes
autoimmunity in mice with specific genetic backgrounds.
Augmented Expression of Inflammatory Mediators in the Joints
of IL-1ra2/2 Mice. We then investigated the pathogenesis
of arthritis and autoimmunity. It was conceivable that the
deficiency of IL-1ra could exaggerate IL-1 signaling, be-
cause IL-1ra is a competitive inhibitor of IL-1a and IL-1b.
As IL-1 is known to induce various inflammatory cytokines,
we analyzed expression of inflammatory mediators in the
joints of IL-1ra2/2 mice to examine whether IL-1 signal-
Figure 2. Incidence of arthritis in BALB/cA IL-1ra2/2 mice. (a) Inci-
dence of arthritis in IL-1ra2/2 mice. Development of arthritis was in-
spected weekly, and the percentage of arthritic mice (grade $1) is shown.
(b) Arthritic severity score of IL-1ra2/2 mice. The average scores of the
mice with or without lesions are shown. Male mice: j, n 5 10; female
mice: d, n 5 20. Average 6 SEM is indicated. w, wk.
Table I. Incidence of Arthritis in IL-1ra2/2 Mice in Different 
Genetic Backgrounds
Age BALB/cA C57BL/6J
129 3
C57BL/6J
wk
8 24/30 (80) 0/56 (0) 0/114 (0)
16 56/56 (100) 0/56 (0) 0/114 (0)
24 ND 1/13 (8) 0/17 (0)
32 ND 2/13 (15) 0/2 (0)
48 2/2 (100) 2/7 (29) ND
Arthritic mice/total mice examined. Numbers in parentheses show the
incidence (%) of arthritic mice.317 Horai et al.
ing is augmented in these mice. As shown in Fig. 4, the IL-
1b mRNA level was increased 10-fold in arthritic joints at
16 wk of age (grade 5 6) compared with IL-1ra1/1 mice.
The expression levels of IL-6 and TNF-a were also aug-
mented in the arthritic joints, although the augmentation
of TNF-a was less intensive (IL-6, 10–26-fold; TNF-a,
1.2–1.5-fold). On the other hand, the expression level of
IL-1a was rather suppressed (1/3–1/2). The COX-2
mRNA level was elevated 2.5–3.5-fold in 16-wk-old ar-
thritic mice, coinciding with inflammation in the joints.
The expression levels of both IL-1RI and IL-1RII were
also increased twofold at 16 wk of age.
Interestingly, the augmentation of these inflammatory
mediator genes was also observed in the joints before onset
of the disease (Fig. 4, a and b). The expression levels of
IL-1b were elevated 2–3-fold in the nonarthritic joints at
4 wk and 1.5–2-fold at 10–12-wk of age, respectively. The
IL-6 and TNF-a expression levels were also elevated 2–4-
and 1.5–2-fold at 10–12 wk of age, respectively. It was
thus shown that IL-1ra deficiency causes augmentation of
proinflammatory cytokines and inflammatory mediators even
before onset of the disease, suggesting that the low level of
IL-1 that is expressed under normal conditions induces the
inflammatory genes in these mutant mice.
Discussion
In this report, we have shown that deficiency of the
IL-1ra gene causes autoimmunity and arthritis, emphasizing
the importance of IL-1/IL-1ra balance in maintaining nor-
mal physiology of the joints and homeostasis of the immune
system. We found that the expression of proinflammatory
cytokines such as IL-1b, IL-6, and TNF-a was augmented
in IL-1ra2/2 mouse joints compared with wild-type mice.
In this regard, it is noteworthy that low levels of IL-1a and
IL-1b were expressed constitutively in the normal joints
without any stimulation (Fig. 4). Thus, the fact that proin-
flammatory cytokine expression was enhanced in IL-1ra2/2
mice suggests that IL-1 activity is suppressed by IL-1ra un-
der physiological conditions, and disruption of the IL-1ra
gene exaggerates the action of the basal level IL-1. This ex-
cess IL-1 signal, as well as overproduced proinflammatory
cytokines, is considered to cause inflammation by enhanc-
ing infiltration of inflammatory cells into synovial tissues,
increasing permeability of blood vessels, activating synovial
lining cells to produce collagenases and metalloproteases,
and activating osteoclasts to destruct the bony structure (2).
It is known that these cytokines can also activate the im-
mune system by enhancing recruitment of immune cells,
activating both T cells and B cells, and enhancing antigen
presentation (19, 20). This cytokine overproduction may
also explain why autoimmunity developed in these mice.
This autoimmune reaction against self-IgGs and synovial
components may also be involved in the development of
arthritis (21). Consistent with this notion, we found that
IL-1ra2/2 mice on the C57BL/6J background developed
arthritis at a high incidence when these mice were immu-
nized with IIC, suggesting hyperresponsiveness of the im-
mune system in IL-1ra2/2 mice (Saijo, S., R. Horai, and Y.
Iwakura, unpublished observation). We also observed ear-
lier onset and more severe phenotype of the disease on a
DBA/1 background (Saijo, S., and Y. Iwakura, unpublished
observation). Recently, Ma et al. reported a similar obser-
vation (22). These observations indicate that IL-1ra plays
an important role in the regulation of the immune system.
The incidence of arthritis was high only in IL-1ra2/2
Figure 3. Antibody production
in IL-1ra2/2 mice. Serum anti-
body levels in IL-1ra2/2 mice
(2/2) and their wild-type litter-
mates (1/1) were determined by
ELISA at 16 wk of age. (a) Levels
of total IgM, IgG, and IgE in
BALB/cA background mice. (b)
Levels of IgG subclasses in
BALB/cA background mice. (c)
Levels of autoantibodies against
IgG (RF) of IgG class and IgM
class, IIC, and dsDNA in BALB/
cA background mice. (d) Auto-
antibody levels in C57BL/6J
background mice. The serum di-
lution in c and d was 1/25. Au-
toantibody levels were expressed
as the relative absorbance of the
ELISA. Average 6 SD of each
genotype is shown. Open bars:
wild-type mice; n 5 13 (a), n 5
11 (b), n 5 9 (c), and n 5 8 (d).
Shaded bars: IL-1ra2/2 mice; n 5
14 (a), n 5 12 (b), n 5 10 (c),
and n 5 15 (d). Statistical signifi-
cance was calculated by Stu-
dent’s  t test. *P , 0.0001; ‡P ,
0.005; §P , 0.05.318 Autoimmune Arthritis in IL-1 Receptor Antagonist–deficient Mice
mice on the BALB/cA background, and incidence in the
C57BL/6J or 129 3 C57BL/6J hybrid background mice
was low. These observations indicate that susceptibility to
arthritis differs among strains, suggesting that genes other
than IL-1ra are involved in the development of arteritis. In
this regard, Nicklin et al. recently found that arthritis de-
veloped in IL-1ra2/2 mice on the 129 3 MF1 Swiss albino
hybrid background, although they did not observe any joint
abnormality in those mice (22a). Thus, IL-1ra2/2 mice
seem to develop tissue specific inflammation depending on
their genetic backgrounds. These additional pathogenic genes
are now under investigation.
So far, several lines of evidence have suggested that aber-
ration of IL-1a, IL-1b, and IL-1ra genes, which form a gene
cluster on the long arm of chromosome 2, are involved in
inflammatory and autoimmune diseases in humans. For ex-
ample, IL-1a polymorphism was detected in humans, and a
specific variant was suggested to be associated with juvenile
RA (23). Epidemiological studies have also invoked a pos-
sibility that IL-1ra is involved in the epithelial cell manifes-
tations of diseases such as ulcerative colitis, systemic lupus
erythematosus, psoriasis, lichen sclerosus, alopecia areata,
and severity of Sjögren’s syndrome, as these conditions are
associated with a particular type of IL-1ra gene polymor-
phism (24–29). In addition, imbalance between IL-1ra and
IL-1b production was observed in RA patients (30, 31). RA
patients exhibited a lower ratio of IL-1ra/IL-1b in plasma,
even at baseline, in comparison with osteoarthritis or osteo-
myelitis patients (32). This observation suggests that IL-1ra
production may be relatively deficient or inadequate in RA
patients. Thus, it is tempting to speculate that IL-1ra gene
deficiency is also involved in the development of arthritis
in humans. However, so far IL-1ra gene polymorphism has
not been reported in RA in humans. We are now examin-
ing this possibility in RA patients with familial history.
Various animal disease models have been developed to
elucidate the ethiopathogenesis of RA in humans. It is well
known that antigens cross-reactive with synovial compo-
nents, such as IIC, and mycobacteria and streptococcal cell
wall components induce arthritis in animals (33–35). MRL-
lpr/lpr mice, which have a mutation in the fas gene, develop
arthritis spontaneously due to development of autoimmunity
(36). Besides these models, we recently developed an HTLV-I
transgenic mouse model in which autoimmunity was caused
by the action of the tax gene (21, 37). In this report, we
have shown a novel RA model, the BALB/cA IL-1ra2/2
Figure 4. Augmentation of IL-1b, IL-6, TNF-a, COX-2, and IL-1R mRNA expression in the joints of BALB/cA IL-1ra2/2 mice. Total RNA was
isolated from the joints, and poly (A)1 RNA was purified. Expression of the genes for IL-1ra, IL-1a, IL-1b, IL-6, TNF-a, IL-1RI, IL-1RII, and COX-2
was examined by Northern blot hybridization analysis. (a) Lanes 1 and 2 and 5–8, IL-1ra1/1 mice; lanes 3 and 4 and 9–12, IL-1ra2/2 mice. Lanes 1 and
2 and 5–12, nonarthritic mice; lanes 3 and 4, arthritic mice (severity score 5 6). Ages of the mice are indicated at top. The results were reproducible in
three independent experiments. (b) Densitometric analysis of mRNA expression levels. The radioactivity for a band shown in panel a was measured by a
BAS 2000 system and normalized by that of b-actin; the radioactivities of the mutant mice relative to those of age-matched wild-type mice are shown.
White bar, wild-type mouse; black bar, arthritic IL-1ra2/2 mouse; gray bar, nonarthritic IL-1ra2/2 mouse. w, wk.319 Horai et al.
mouse. As the joint pathology and the immunological sta-
tus in this model closely resembles that of RA patients and
the penetrance is complete, these mice should also provide
another useful model for RA in humans.
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